Atopic Dermatitis Drugs Market Size to grow by USD 6204.8 million between 2024-2028

Technavio, a leading provider of market research reports, has released its latest study on Atopic Dermatitis Drugs Market. This report offers a comprehensive analysis of the current market trends, emerging opportunities, and key challenges. The global atopic dermatitis drugs market has witnessed significant growth over the past five years, with vendors implementing various business strategies to expand their product offerings. Notably, mergers and acquisitions (M&A) and technology-related partnerships have been popular approaches to enhance market presence and sales of atopic dermatitis drugs. For instance, Pfizer and Glenmark's collaboration in January 2024 led to the introduction of Abrocitinib, an innovative oral treatment for moderate-to-severe atopic dermatitis, in India. Such strategic moves may boost vendors' profitability by expanding their market reach and product portfolios.

Key Highlights

Growth Projections

The global atopic dermatitis drugs market  size is estimated to grow by USD 6204.8 mn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  10.87% during the forecast period. High prevalence of atopic dermatitis is driving market growth, with a trend towards strategic partnerships and acquisitions  However, side effects associated with corticosteroids  poses a challenge.Key market players include AbbVie Inc., Arcutis Biotherapeutics Inc., Asana BioSciences LLC, Astellas Pharma Inc., Bausch Health Companies Inc., Bayer AG, BiomX Inc., Bristol Myers Squibb Co., Dermavant Sciences Inc., Eli Lilly and Co., Evelo Biosciences Inc., Galderma SA, Incyte Corp., LEO Pharma AS, Maruho Co. Ltd., Novartis AG, Otsuka Holdings Co. Ltd., Pfizer Inc., Sanofi SA, and Viatris Inc..

Know what is trending in the market - Access a free sample report! 

Major Findings

• Atopic dermatitis, a chronic inflammatory skin condition, affects an estimated 15-30% of children and 1-3% of adults worldwide. The high prevalence of this disease necessitates the development and availability of effective treatments. The atopic dermatitis drugs market encompasses a range of pharmaceutical interventions, including topical corticosteroids, calcineurin inhibitors, systemic immunosuppressants, and biologics. These medications aim to alleviate symptoms such as itching, redness, and inflammation, thereby improving patients' quality of life. The market for atopic dermatitis drugs is expected to grow significantly due to the increasing incidence and prevalence of the disease, as well as the development of novel and more effective treatment options.


• The Atopic Dermatitis Drugs Market is experiencing significant growth due to increasing healthcare expenditure and a rising prevalence of atopic dermatitis worldwide. This condition, characterized by chronic inflammation of the skin, affects millions of people, particularly children. Pharmaceutical companies are investing heavily in research and development to bring innovative treatments to market, including topical corticosteroids, calcineurin inhibitors, and biologics. These advanced therapies offer improved efficacy and reduced side effects, making them increasingly popular among patients and healthcare providers. Additionally, growing awareness and education about atopic dermatitis, as well as expanding healthcare coverage, are contributing to the market's expansion.


• Corticosteroids are commonly prescribed medications for managing the symptoms of Atopic Dermatitis. However, their long-term use can result in various side effects. These include thinning of the skin, increased susceptibility to infections, and development of stretch marks. In children, corticosteroid use may lead to growth suppression and delayed height development. It is essential to monitor patients closely and minimize the use of corticosteroids, especially potent forms, to mitigate these risks. Regularly consulting a healthcare professional is recommended to determine the most effective and safe treatment plan.


• The Atopic Dermatitis Drugs Market is subject to stringent regulatory guidelines. Regulatory bodies such as the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) impose rigorous approval processes to ensure the safety and efficacy of drugs used in the treatment of atopic dermatitis. These guidelines include clinical trials, pharmacovigilance, and quality control measures. Adherence to these regulations is crucial to bring new treatments to market and maintain patient trust.

Market Research Overview

The Atopic Dermatitis Drugs Market is a significant segment of the larger global pharmaceuticals industry. This market encompasses entities involved in the research and development (R&D) or manufacturing of various drug classes, including generic and non-generic medications, as well as veterinary drugs. According to Technavio, the global pharmaceuticals market size is determined by the collective revenue generated by providers of equipment, supplies, pharmaceuticals, biotechnology, and life sciences tools and services. Key growth drivers for this market include the increasing global population aging, with the proportion of individuals over 60 years old in the US projected to reach 25% by 2050, and Europe projected to reach a similar ratio by 2030.

The Atopic Dermatitis Drugs Market is experiencing significant growth, fueled by the High prevalence of atopic dermatitis. Businesses are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.

For insights on company offerings- Request a sample report!

Regional Insights

The Atopic Dermatitis Drugs Market represents a significant business opportunity due to the increasing prevalence of atopic dermatitis worldwide. Key players in this market include Pfizer, Novartis, and Sanofi, who dominate with their innovative treatments, such as biologics and topical corticosteroids. Growth is driven by rising awareness, advances in research, and the unmet medical need for effective and safe therapies for this chronic condition. Market size is projected to expand at a robust CAGR through 2027.

Research Analysis Overview

Atopic Dermatitis (AD), also known as eczema, is a chronic inflammatory skin condition affecting hand dermatitis and hand eczema, particularly in children. Traditional treatments include topical corticosteroids, oil stripping soaps, and antimicrobials to manage symptoms and prevent infections. However, long-term use of topical steroids can lead to side effects and healthcare access disparities. Recent advances include Crisaborole ointment, a novel phosphodiesterase-4 inhibitor approved for mild-to-moderate AD in pediatric patients. New products like Ruxolitinib Cream, a JAK1/JAK2 inhibitor, show promise for treating severe AD. Regulatory complexities and healthcare expenditure hinder widespread adoption of these novel treatments. Westernized lifestyles and handwashing contribute to disease prevalence. Telemedicine adoption may improve access to care, but it faces challenges in diagnosing and monitoring AD. Hospital pharmacies play a crucial role in managing biologic therapies for AD. Drug approvals for topical treatments and targeted therapies continue, with ongoing research exploring the potential of novel treatments like biologics. Despite these advances, addressing healthcare access disparities and regulatory complexities remains essential to improving the lives of those living with AD.

About Technavio                                                                        

Technavio is a global market research company offering comprehensive reports and insights on various industries. Our research helps businesses make informed decisions by providing actionable data and trends. Technavio is based on four simple principles: easy-to-access reports, robust industry coverage, a focus on new and emerging technologies, and competitive pricing. We believe in helping companies and executives become better equipped to make faster, sounder, and more effective decisions. Technavio is one of the most influential market research and advisory firms in the world. We work with business and technology leaders to provide cutting-edge market research and insights to companies. 

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/